Actively Recruiting
Selective Laser Trabeculoplasty Versus Latanoprost as First Line Treatments for Primary Open-angle Glaucoma and Ocular Hypertension: A Comparative Analysis
Led by Lagos State Health Service Commission · Updated on 2025-12-30
138
Participants Needed
1
Research Sites
8 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are comparing the short-term effectiveness and safety of selective laser trabeculoplasty (SLT) against 0.005% latanoprost eye drops for lowering eye pressure in patients newly diagnosed with early to moderate primary open-angle glaucoma (POAG) or ocular hypertension (OHT). The study aims to determine if SLT is as effective and safe as latanoprost eye drops when used as the first treatment option. It also evaluates how each treatment affects patients' quality of life. Participants will be randomly assigned to one of two groups. One group will use 0.005% latanoprost eye drops every night for three months, while the other will receive a one-time SLT laser treatment. Intraocular pressure will be checked regularly over the three-month period, and any side effects will be recorded during follow-up visits. The study will take place at the Lagos State University Teaching Hospital's glaucoma clinic and will involve monitoring eye pressure changes over three months. Participants will have regular assessments to track treatment effects, side effects, and quality of life. The trial is designed to provide detailed information about how these treatments perform as initial therapy for glaucoma or ocular hypertension.
CONDITIONS
Brief Title
A Comparative Study of Intraocular Pressure Control Using Selective Laser Trabeculoplasty and Latanoprost as Initial Treatments for Primary Open Angle Glaucoma and Ocular Hypertension in Lagos State University Teaching Hospital
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 18 years and above
- Newly diagnosed with Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
- Elevated intraocular pressure greater than 21 mmHg based on three measurements on different clinic visits
- Early or moderate glaucoma with specific eye exam findings (cup-disc ratio 0.5 to 0.7, visual field mean deviation between -6 dB and -12 dB, disc damage likelihood score 5 to 7)
- Agree to participate after informed consent
You will not qualify if you...
- Previous medical, surgical, or laser treatment for glaucoma
- Diagnosis of primary congenital glaucoma or secondary glaucoma
- Advanced glaucoma with more severe eye exam findings (cup-disc ratio over 0.8, visual field mean deviation worse than -12 dB, disc damage likelihood score 8 or above)
- Cloudy cornea or corneal opacity affecting eye exams
- Media opacities like cataracts, vitreous haze, or hemorrhage preventing proper eye examination
- Previous eye surgeries such as cataract surgery or trabeculectomy
- History of ocular trauma or uveitis
- Pregnant or lactating women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 12 months
Participants receive either selective laser trabeculoplasty or daily latanoprost eye drops to reduce intraocular pressure.
Weekly visits for up to 12 weeks and additional visits as needed
Trial Site Locations
Total: 1 location
1
Lagos State University teaching Hospital Eye Institute
Ikeja, Lagos, Nigeria
Actively Recruiting
Research Team
A
Anne I. Abang-Obi, MBBS
C
Chidinma C. Onyejekwe, FMCOph
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here